Literature DB >> 24534296

Agreement between different survey instruments to assess incident and prevalent tumors and medical records - results of the Heinz Nixdorf Recall Study.

Beate Bokhof1, Lewin Eisele2, Raimund Erbel3, Susanne Moebus2.   

Abstract

OBJECTIVE: The validity of participants' self-reports via questionnaires or interviews in epidemiological studies remains questionable. We examined the agreement of tumors, reported via different survey instruments, with medical records.
METHODS: Within the Heinz Nixdorf Recall Study, comprising 4814 subjects aged 45-75 years, tumors were assessed via different survey tools at baseline and 8-year-follow up (FU): personal interviews (CAPI), self-administered questionnaires (SA-Q), physical examinations, short questionnaire/non-responder questionnaire (S-/N-Q) and telephone interviews. Information on each self-reported tumor was coded via ICD-10, WHO-Version 2010, and evaluated against medical records.
RESULTS: During FU, 95% of 1083 self-reported incident tumors in 623 individuals, at baseline, 65% of 473 prevalent tumors in 406 individuals could be evaluated. Agreement of the main assessment tools, CAPI and SA-Q, with medical records was 90.1% and 88.4% (FU) and 91.0% (baseline-CAPI). Best agreement was in tumors of prostate (baseline-CAPI: 97.8%; 5-year-FU-CAPI: 96.9%, SA-Q: 95.7%) and breast (baseline-CAPI: 93.2%; 5-year-FU-CAPI: 100.0%, SA-Q: 98.8%). DISCUSSION: Agreement of CAPI and SA-Q with medical records was good. To assess incident tumors, SA-Q emerged as favorable, as it is least expensive and easy to be applied. Especially for tumors of prostate and breast, cost-intensive and time-consuming validation with medical records may not be necessary.
Copyright © 2014 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Agreement; Assessment tools; Medical records; Tumor diagnoses; Validity

Mesh:

Year:  2014        PMID: 24534296     DOI: 10.1016/j.canep.2014.01.002

Source DB:  PubMed          Journal:  Cancer Epidemiol        ISSN: 1877-7821            Impact factor:   2.984


  2 in total

1.  Agreement between self-reported and central cancer registry-recorded prevalence of cancer in the Alaska EARTH study.

Authors:  Sarah H Nash; Gretchen Day; Vanessa Y Hiratsuka; Garrett L Zimpelman; Kathryn R Koller
Journal:  Int J Circumpolar Health       Date:  2019-12       Impact factor: 1.228

2.  Monoclonal gammopathy of undetermined significance is associated with prostate cancer in a population-based cohort study.

Authors:  Nicola Hornung; Mirjam Frank; Nico Dragano; Jan Dürig; Ulrich Dührsen; Susanne Moebus; Raimund Erbel; Andreas Stang; Karl-Heinz Jöckel; Börge Schmidt
Journal:  Sci Rep       Date:  2021-09-29       Impact factor: 4.379

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.